Inclusion Criteria:

- adenocarcinoma breast cancer

- ECOG performance status of 0 or 1

- peripheral neuropathy less than or equal to 1

- discontinued hormonal therapy as a chemoprevention while onstudy

- LVEF by MUGA > 55%?

- Absolute neutrophil count (ANC)> 1000/µL)

- platelet count > 100,000/µL)

- SGOT OR SGPT < 92.5 units/L

Exclusion Criteria:

- Stage IV breast cancer

- any chemotherapy, radiation therapy, immunotherapy, or biotherapy for a CURRENT
breast cancer

- pregnant or lactating patients

- active second malignancy, other than adequately treated non-melanoma skin cancers or
in situ cervical cancer

- previous allergy/hypersensitivity to Doxorubicin, Cyclophosphamide, Paclitaxel, or
other drugs formulated in Cremophor EL?

- unstable angina, congestive heart failure, current use of digitalis, beta-blockers,
or calcium blockers for therapy of congestive heart failure, arrhythmia requiring
medical therapy, or a history of a myocardial infarction within 12 months

- psychiatric illness that prevents her from understanding the nature of this study and
complying with protocol requirements?

- active, unresolved infections

- sensitivity to E. coli derived proteins

- prior chemotherapy with an anthracycline

- prior Herceptin therapy